JP2024506612A5 - - Google Patents

Info

Publication number
JP2024506612A5
JP2024506612A5 JP2023547775A JP2023547775A JP2024506612A5 JP 2024506612 A5 JP2024506612 A5 JP 2024506612A5 JP 2023547775 A JP2023547775 A JP 2023547775A JP 2023547775 A JP2023547775 A JP 2023547775A JP 2024506612 A5 JP2024506612 A5 JP 2024506612A5
Authority
JP
Japan
Prior art keywords
cancer
aforementioned
adenocarcinoma
cell carcinoma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/073906 external-priority patent/WO2022170974A1/en
Publication of JP2024506612A publication Critical patent/JP2024506612A/ja
Publication of JP2024506612A5 publication Critical patent/JP2024506612A5/ja
Pending legal-status Critical Current

Links

JP2023547775A 2021-02-09 2022-01-26 Ｐａｒｐ７阻害剤として有用な三環式誘導体 Pending JP2024506612A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076144 2021-02-09
CN2021076144 2021-02-09
CNPCT/CN2021/091050 2021-04-29
CN2021091050 2021-04-29
CNPCT/CN2021/117189 2021-09-08
CN2021117189 2021-09-08
CNPCT/CN2021/119368 2021-09-18
CN2021119368 2021-09-18
CN2021124714 2021-10-19
CNPCT/CN2021/124714 2021-10-19
CN2021128807 2021-11-04
CNPCT/CN2021/128807 2021-11-04
CNPCT/CN2021/129056 2021-11-05
CN2021129056 2021-11-05
PCT/CN2022/073906 WO2022170974A1 (en) 2021-02-09 2022-01-26 Tricyclic derivatives useful as parp7 inhibitors

Publications (2)

Publication Number Publication Date
JP2024506612A JP2024506612A (ja) 2024-02-14
JP2024506612A5 true JP2024506612A5 (https=) 2025-01-31

Family

ID=82838260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547775A Pending JP2024506612A (ja) 2021-02-09 2022-01-26 Ｐａｒｐ７阻害剤として有用な三環式誘導体

Country Status (11)

Country Link
US (1) US20240336629A1 (https=)
EP (1) EP4291560A4 (https=)
JP (1) JP2024506612A (https=)
KR (1) KR20230167755A (https=)
CN (1) CN116848114A (https=)
AU (1) AU2022220924A1 (https=)
BR (1) BR112023015721A2 (https=)
CA (1) CA3210885A1 (https=)
TW (1) TW202246266A (https=)
UY (1) UY39625A (https=)
WO (1) WO2022170974A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116724044B (zh) * 2021-02-03 2025-10-31 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN117396485B (zh) * 2021-05-25 2026-01-30 轩竹生物科技股份有限公司 Parp7抑制剂
WO2024037558A1 (en) * 2022-08-17 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. Solid forms of compound i or salts thereof
CN117551080A (zh) * 2022-11-11 2024-02-13 杭州师范大学 一种靶向降解parp7的protac化合物及其制备方法与应用
CN119330972A (zh) * 2023-09-01 2025-01-21 重庆华森英诺生物科技有限公司 Parp7抑制剂及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
WO2021047406A1 (zh) * 2019-09-10 2021-03-18 四川科伦博泰生物医药股份有限公司 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2021087025A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116724044B (zh) * 2021-02-03 2025-10-31 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用

Similar Documents

Publication Publication Date Title
JP2024506612A5 (https=)
He et al. WNT/β-catenin signaling in the development of liver cancers
Zheng et al. Lysine demethylase 5B (KDM5B): a potential anti-cancer drug target
Roviello et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments
JP2022548057A5 (https=)
JP2011521618A5 (https=)
Jiang CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy
Zhan et al. Digestive cancers: mechanisms, therapeutics and management
JP2020508302A5 (https=)
Espersen et al. Clinical implications of intestinal stem cell markers in colorectal cancer
JP2007153894A5 (https=)
JP2022153392A5 (https=)
Mayer et al. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years
RU2014102935A (ru) Кризотиниб для применения в лечении рака
JP2021520349A5 (https=)
GEAP202416383A (en) Use of medicament in treatment of tumor disease
Pogorzelska et al. Novel 2-(2-alkylthiobenzenesulfonyl)-3-(phenylprop-2-ynylideneamino) guanidine derivatives as potent anticancer agents–Synthesis, molecular structure, QSAR studies and metabolic stability
Chen et al. Coptidis rhizoma and berberine as anti-cancer drugs: A 10-year updates and future perspectives
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
JP2023515687A5 (https=)
JP2025507923A5 (https=)
JP2013537228A5 (https=)
Terada Protein expression and gene mutation status of KIT and PDGFRA in renal cell carcinoma
WO2006014903A3 (en) Compositions and methods of use for adam12 antagonists in treating disease
JPWO2023048231A5 (https=)